Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Dose-Ranging Pharmacokinetic Study Comparing Investigational Oral Formulation with the Current Intravenous Formulation of Edaravone

Trial Profile

A Phase 1, Dose-Ranging Pharmacokinetic Study Comparing Investigational Oral Formulation with the Current Intravenous Formulation of Edaravone

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2018

At a glance

  • Drugs Edaravone (Primary) ; Edaravone
  • Indications Amyotrophic lateral sclerosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 02 Dec 2018 New trial record
    • 15 Nov 2018 Results presented in a Media Release
    • 15 Nov 2018 According to a Mitsubishi Tanabe Pharma America media release, data collection from this study is ongoing and the latest results and its anticipated development plan will be presented at the upcoming Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top